A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder

Abstract

As the opioid epidemic continues to grow across the United States, the number of patients requiring treatment for opioid use disorder continues to climb. Although medication-assisted treatment presents a highly effective tool that can help address this epidemic, its use has been limited. Nonetheless, with easier dosing protocols (compared to the more complex dosing required of methadone due to its long and variable half-life) and fewer prescribing limitations (may be prescribed outside the setting of federally approved clinics), the increase in buprenorphine use in the United States has been dramatic in recent years. Despite buprenorphine’s demonstrated efficacy, patient-specific factors can alter the response to the medications, which may lead to treatment failure in some patients. Clinical characteristics (sex, concurrent medications, and mental health comorbidities) as well as social determinants of health (housing status, involvement with the criminal justice system, and socioeconomic status) may impact treatment outcomes. Furthermore, a growing body of data suggests that genetic variations can alter pharmacological effects and influence therapeutic response. This review will cover the available pharmacogenomic data for the use of buprenorphine in the management of opioid use disorders. Pharmacogenomic determinants that affect opioid receptors, the dopaminergic system, metabolism of buprenorphine, and adverse events are discussed. Although much of the existing data comes from observational studies, clinical research is ongoing. Nevertheless, the development of pharmacogenomic-guided strategies has the potential to reduce opioid misuse, improve clinical outcomes, and save healthcare resources.

Keywords

Pharmacogenomics / pharmacogenetics / buprenorphine / opioid use disorder / opioids / personalized medicine / medication-assisted treatment / buprenorphine/naloxone

References

[1] Center for Behavioral Health Statistics and Quality. 2015 National Survey on Drug Use and Health: Detailed Tables. Substance Abuse and Mental Health Services Administration; 2016. Available from: https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015.pdf. [Last accessed on 20 Jul 2020]

[2] SchuckitMA.Treatment of Opioid-Use Disorders..N Engl J Med2016;375:357-68

[3] Centers for Disease Control and Prevention. Understanding the Epidemic. Opioid Overdose. Available from: https://www.cdc.gov/drugoverdose/epidemic/index.html. [Last accessed on 14 Jul 2020]

[4] National Academies of Sciences, Engineering, and Medicine. Medications for opioid use disorder save lives.2019;National Academies Press

[5] FlorenceCS,LuoF.The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013..Med Care2016;54:901-6 PMCID:PMC5975355

[6] JiangR,LeeTA.The societal cost of heroin use disorder in the United States..PLoS One2017;12:e0177323 PMCID:PMC5448739

[7] FirstMB.DSM-5 handbook of differential diagnosis.2013;American Psychiatric Pub

[8] WoodyGE,SubramaniamG,BogenschutzM.Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial..JAMA2008;300:2003-11 PMCID:PMC2610690

[9] MatsonSC,Abdel-RasoulM.A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic..J Addict Med2014;8:176-82

[10] HadlandSE,RodeanJ,LevyS.Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder..JAMA Pediatr2018;172:1029-37 PMCID:PMC6218311

[11] ClaySW.Treatment of addiction in the elderly..Aging health2010;6:177-89

[12] KotelchuckM,BelanoffC,Babakhanlou-ChaseH.The prevalence and impact of substance use disorder and treatment on maternal obstetric experiences and birth outcomes among singleton deliveries in massachusetts..Matern Child Health J2017;21:893-902 PMCID:PMC5380534

[13] KaltenbachK.Developmental outcome of children born to methadone maintained women: a review of longitudinal studies..Neurobehav Toxicol Teratol1984;6:271-5

[14] JonesHE,HeilSH,CoyleMG.Neonatal abstinence syndrome after methadone or buprenorphine exposure..N Engl J Med2010;363:2320-31 PMCID:PMC3073631

[15] SchwartzRP,O’GradyKE,WarrenG.Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009..Am J Public Health2013;103:917-22 PMCID:PMC3670653

[16] MattickRP,KimberJ,BreenR.Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews.1996;ChichesterJohn Wiley & Sons, Ltd

[17] KakkoJ,KreekMJ.1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial..Lancet2003;361:662-8

[18] BartG.Maintenance medication for opiate addiction: the foundation of recovery..J Addict Dis2012;31:207-25 PMCID:PMC3411273

[19] GowingL,BornemannR,AliR.Oral substitution treatment of injecting opioid users for prevention of HIV infection..Cochrane Database Syst Rev2011;10:CD004145

[20] NichollsL,RuetschC.Opioid dependence treatment and guidelines..J Manag Care Pharm2010;16:S14-21

[21] AlderksCE.Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003-2015 (Update). The CBHSQ report.2017;Rockville, USSubstance Abuse and Mental Health Services Administration

[22] PotterJS,MarinoEN,DoddDR.The multi-site prescription opioid addiction treatment study: 18-month outcomes..J Subst Abuse Treat2015;48:62-9 PMCID:PMC4250351

[23] WeissRD,GriffinML,FitzmauriceGM.Long-term outcomes from the national drug abuse treatment clinical trials network prescription opioid addiction treatment study..Drug Alcohol Depend2015;150:112-9 PMCID:PMC4407806

[24] JonesHE,JohnsonRE.Males and females differ in response to opioid agonist medications..Am J Addict2005;14:223-33

[25] McCance-KatzEF,NallaniS.Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review..Am J Addict2010;19:4-16 PMCID:PMC3334287

[26] LitzM.The impact of mental health comorbidities on adherence to buprenorphine: A claims based analysis..Am J Addict2017;26:859-63

[27] LoA,HayashiK,NosovaE.Factors associated with methadone maintenance therapy discontinuation among people who inject drugs..J Subst Abuse Treat2018;94:41-6 PMCID:PMC6375706

[28] LopianKM,KulakJA,BlondellRD.A retrospective analysis of treatment and retention outcomes of pregnant and/or parenting women with opioid use disorder..J Subst Abuse Treat2019;97:1-6

[29] CristRC,DoyleGA,DechairoBM.Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate..Am J Drug Alcohol Abuse2018;44:431-40 PMCID:PMC5940523

[30] CristRC,NelsonEC,MartinNG.A polymorphism in the OPRM1 3’-untranslated region is associated with methadone efficacy in treating opioid dependence..Pharmacogenomics J2018;18:173-9 PMCID:PMC5468510

[31] CristRC,AngA,LohoffFW.An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans..Neuropsychopharmacology2013;38:2003-10 PMCID:PMC3746708

[32] CrettolS,BessonJ,HämmigR.ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment..Clin Pharmacol Ther2006;80:668-81

[33] CsajkaC,GuidiM.Population genetic-based pharmacokinetic modeling of methadone and its relationship with the QTc interval in opioid-dependent patients..Clin Pharmacokinet2016;55:1521-33

[34] LevranO,HamonS,AdelsonM.CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction..Addict Biol2013;18:709-16 PMCID:PMC3735354

[35] PengS,DuJ,PanS.Methadone dosage and plasma levels, SNPs of OPRM1 gene and age of first drug use were associated with outcomes of methadone maintenance treatment..Front Genet2018;9:450 PMCID:PMC6216325

[36] TianJN,TsouHH,HsiaoCF.UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients..Pharmacogenomics2012;13:879-88

[37] BerrettiniW.A brief review of the genetics and pharmacogenetics of opioid use disorders..Dialogues Clin Neurosci2017;19:229-36 PMCID:PMC5741106

[38] CristRC,BerrettiniWH.Pharmacogenetics of opioid use disorder treatment..CNS Drugs2018;32:305-20 PMCID:PMC5935553

[39] GerraG,ZaimovicA,BussandriM.Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome..Drug Alcohol Depend2004;75:37-45

[40] SerafiniG,CanepaG,ValcheraA.The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review..Int J Mol Sci2018;19:2410 PMCID:PMC6121503

[41] ToceMS,BurnsMM.Pharmacologic treatment of opioid use disorder: a review of pharmacotherapy, adjuncts, and toxicity..J Med Toxicol2018;14:306-22 PMCID:PMC6242798

[42] ZhangH,YangBZ,GelernterJ.The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk..Mol Psychiatry2008;13:531-43 PMCID:PMC3163084

[43] BeerB,PavlicM,GiacomuzziS.Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study..PLoS One2013;8:e75359 PMCID:PMC3783401

[44] SaxonAJ,HillhouseM,HassonA.Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial..Drug Alcohol Depend2013;128:71-6 PMCID:PMC3543467

[45] BlancoF,LabradorJ,Gonzalez-SarmientoR.Influence of UGT2B7, CYP3A4, and OPRM1 gene polymorphisms on transdermal buprenorphine pain control in patients with critical lower limb ischemia awaiting revascularization..Pain Pract2016;16:842-9

[46] MurielJ,PlanellesB,PugaC.OPRM1 influence on and effectiveness of an individualized treatment plan for prescription opioid use disorder patients..Ann N Y Acad Sci2018;1425:82-93

[47] NelsonEC,HeathAC,AgrawalA.Association of OPRD1 polymorphisms with heroin dependence in a large case-control series..Addict Biol2014;19:111-21 PMCID:PMC3867542

[48] CristRC,FurnariMA,DoyleGA.Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder..Pharmacogenomics J2019;19:260-8 PMCID:PMC6486881

[49] ClarkeTK,AngA,LohoffFW.Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females..Pharmacogenomics J2014;14:303-8 PMCID:PMC3988270

[50] MoodyDE,MorrisonJ.Gender differences in pharmacokinetics of maintenance dosed buprenorphine..Drug Alcohol Depend2011;118:479-83 PMCID:PMC3162987

[51] ZubietaJK,FrostJJ.Gender and age influences on human brain mu-opioid receptor binding measured by PET..Am J Psychiatry1999;156:842-8

[52] UngerA,WinklbaurB.Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine..J Addict Dis2010;29:217-30 PMCID:PMC2858865

[53] NunesEV.Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis..JAMA2004;291:1887-96

[54] BrewerDD,HaggertyK,FlemingCB.A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction..Addiction1998;93:73-92

[55] GerraG,LeonardiC,MaremmaniI.Association between gene variants and response to buprenorphine maintenance treatment..Psychiatry Res2014;215:202-7

[56] RussoSJ.The brain reward circuitry in mood disorders..Nat Rev Neurosci2013;14:609-25 PMCID:PMC3867253

[57] WeeS.The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse..Psychopharmacology2010;210:121-35 PMCID:PMC2879894

[58] BlumK,WoodRC,ChenTJ.The D2 dopamine receptor gene as a determinant of reward deficiency syndrome..J R Soc Med1996;89:396-400 PMCID:PMC1295855

[59] LawfordBR,NobleEP,RowellJ.The D2 dopamine receptor A1 allele and opioid dependence: association with heroin use and response to methadone treatment..Am J Med Genet2000;96:592-8

[60] BarrattDT,SomogyiAA.Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments..Am J Med Genet B Neuropsychiatr Genet2006;141:323-31

[61] PicardN,DjebliN.In vitro metabolism study of buprenorphine: evidence for new metabolic pathways..Drug Metab Dispos2005;33:689-95

[62] ConeEJ,YousefnejadD,JohnsonRE.The metabolism and excretion of buprenorphine in humans..Drug Metab Dispos1984;12:577-81

[63] ZangerUM.Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation..Pharmacol Ther2013;138:103-41

[64] RouguiegK,SauvageFL,MarquetP.Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes..Drug Metab Dispos2010;38:40-5

[65] EttienneEB,ManenoM,WilsonB.Pharmacogenomics-guided policy in opioid use disorder (OUD) management: an ethnically-diverse case-based approach..Addict Behav Rep2017;6:8-14 PMCID:PMC5800559

[66] Westlind-JohnssonA,HuennemeyerA,LahuG.Identification and characterization of CYP3A4* 20, a novel rare CYP3A4 allele without functional activity..Clin Pharmacol Ther2006;79:339-49

[67] EttienneEB,ManenoMK,EzeudeG.Pharmacogenomics and opioid use disorder: clinical decision support in an African American cohort..J Natl Med Assoc2019;111:674-81

[68] MurielJ,BarrachinaJ,FlorA.Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients..Basic Clin Pharmacol Toxicol2019;124:439-48

[69] Whirl-CarrilloM,HebertJM,SangkuhlK.Pharmacogenomics knowledge for personalized medicine..Clin Pharmacol Ther2012;92:414-7 PMCID:PMC3660037